Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Systemic Inflammatory Response Syndrome

ClinicalTrials.gov lists 3,570 trials for Systemic Inflammatory Response Syndrome or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 26.

MeSH D018746 Pathological Conditions, Signs and Symptoms C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 113 Phase 1/2 Phase 1/2 63 Phase 2 Phase 2 278 Phase 2/3 Phase 2/3 79 Phase 3 Phase 3 281 Phase 4 Phase 4 261 Not applicable Not applicable 926 Observational Observational 1,562 Phase 1 Phase 1 113 Phase 1/2 Phase 1/2 63 Phase 2 Phase 2 278 Phase 2/3 Phase 2/3 79 Phase 3 Phase 3 281 Phase 4 Phase 4 261 Not applicable Not applicable 926 Observational Observational 1,562

Trials per phase (log scale)

1 more section with rows

195 of the 3,570 trials are tagged with Systemic Inflammatory Response Syndrome itself; the rest are tagged with a narrower condition beneath it.

Get the Systemic Inflammatory Response Syndrome report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Systemic Inflammatory Response Syndrome trials start? (35)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 9 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 246

1990: 1 trials (Phase 3 1) 1991: 1 trials (Observational 1) 1992: 1 trials (Phase 1 1) 1993: 2 trials (Phase 4 1, Phase 3 1) 1996: 3 trials (Not applicable 1, Phase 4 1, Phase 1/2 1) 1997: 2 trials (Not applicable 1, Phase 4 1) 1998: 2 trials (Phase 1 2) 1999: 9 trials (Observational 2, Not applicable 1, Phase 3 4, Phase 2/3 1, Phase 2 1) 2000: 8 trials (Observational 3, Not applicable 1, Phase 3 2, Phase 2/3 1, Phase 1 1) 2001: 10 trials (Observational 2, Phase 4 1, Phase 3 3, Phase 2 3, Phase 1/2 1) 2002: 20 trials (Observational 4, Not applicable 2, Phase 4 4, Phase 3 7, Phase 2 3) 2003: 30 trials (Observational 5, Not applicable 4, Phase 4 5, Phase 3 8, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 4) 2004: 41 trials (Observational 8, Not applicable 11, Phase 4 6, Phase 3 7, Phase 2/3 2, Phase 2 4, Phase 1 3) 2005: 46 trials (Observational 14, Not applicable 9, Phase 4 6, Phase 3 4, Phase 2/3 3, Phase 2 6, Phase 1 4) 2006: 71 trials (Observational 22, Not applicable 17, Phase 4 9, Phase 3 9, Phase 2/3 3, Phase 2 6, Phase 1/2 2, Phase 1 3) 2007: 75 trials (Observational 28, Not applicable 15, Phase 4 10, Phase 3 9, Phase 2/3 1, Phase 2 9, Phase 1 3) 2008: 101 trials (Observational 38, Not applicable 17, Phase 4 13, Phase 3 14, Phase 2/3 5, Phase 2 11, Phase 1/2 2, Phase 1 1) 2009: 96 trials (Observational 54, Not applicable 14, Phase 4 7, Phase 3 10, Phase 2/3 1, Phase 2 4, Phase 1/2 2, Phase 1 4) 2010: 95 trials (Observational 35, Not applicable 28, Phase 4 6, Phase 3 6, Phase 2/3 1, Phase 2 12, Phase 1/2 2, Phase 1 5) 2011: 108 trials (Observational 44, Not applicable 31, Phase 4 4, Phase 3 11, Phase 2/3 4, Phase 2 3, Phase 1/2 1, Phase 1 10) 2012: 122 trials (Observational 55, Not applicable 25, Phase 4 9, Phase 3 12, Phase 2/3 1, Phase 2 11, Phase 1/2 5, Phase 1 4) 2013: 131 trials (Observational 55, Not applicable 36, Phase 4 10, Phase 3 12, Phase 2/3 4, Phase 2 9, Phase 1 5) 2014: 146 trials (Observational 69, Not applicable 37, Phase 4 13, Phase 3 10, Phase 2/3 4, Phase 2 7, Phase 1/2 3, Phase 1 3) 2015: 133 trials (Observational 60, Not applicable 38, Phase 4 13, Phase 3 5, Phase 2/3 2, Phase 2 4, Phase 1/2 5, Phase 1 6) 2016: 165 trials (Observational 80, Not applicable 46, Phase 4 14, Phase 3 7, Phase 2/3 2, Phase 2 11, Phase 1 5) 2017: 168 trials (Observational 76, Not applicable 51, Phase 4 12, Phase 3 9, Phase 2/3 2, Phase 2 12, Phase 1/2 2, Phase 1 4) 2018: 194 trials (Observational 81, Not applicable 57, Phase 4 11, Phase 3 15, Phase 2/3 5, Phase 2 17, Phase 1/2 5, Phase 1 3) 2019: 230 trials (Observational 106, Not applicable 65, Phase 4 11, Phase 3 20, Phase 2/3 5, Phase 2 18, Phase 1/2 2, Phase 1 3) 2020: 246 trials (Observational 106, Not applicable 53, Phase 4 11, Phase 3 23, Phase 2/3 8, Phase 2 32, Phase 1/2 8, Phase 1 5) 2021: 213 trials (Observational 87, Not applicable 65, Phase 4 10, Phase 3 14, Phase 2/3 6, Phase 2 22, Phase 1/2 3, Phase 1 6) 2022: 222 trials (Observational 113, Not applicable 55, Phase 4 12, Phase 3 13, Phase 2/3 2, Phase 2 18, Phase 1/2 4, Phase 1 5) 2023: 210 trials (Observational 100, Not applicable 59, Phase 4 15, Phase 3 11, Phase 2/3 4, Phase 2 12, Phase 1/2 3, Phase 1 6) 2024: 212 trials (Observational 105, Not applicable 56, Phase 4 12, Phase 3 11, Phase 2/3 3, Phase 2 15, Phase 1/2 4, Phase 1 6) 2025: 178 trials (Observational 88, Not applicable 50, Phase 4 15, Phase 3 7, Phase 2/3 3, Phase 2 6, Phase 1/2 2, Phase 1 7)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 244
2025 178
2024 212
2023 210
2022 222
2021 213
2020 246
2019 230
2018 194
2017 168

Showing 10 of 35 earlier years.

Start your 14-day trial Email me all 35 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 260 trials starting in 2026 and about 220 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 211 trials still running at the 2026-10-09 snapshot; registered median of 21 months across 2,051 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Systemic Inflammatory Response Syndrome trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 113
Phase 1/2 63
Phase 2 278
Phase 2/3 79
Phase 3 281
Phase 4 261
Not applicable 926
Observational 1,562
Expanded access 7

How many Systemic Inflammatory Response Syndrome trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 212
Recruiting 357
Enrolling by invitation 22
Active, not recruiting 67
Completed 1,828

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Systemic Inflammatory Response Syndrome trials? (2)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 26
Pfizer 21

Which drugs are being tested for Systemic Inflammatory Response Syndrome? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Vitamin C 32
Norepinephrine 30
Endotoxin 21
DEXMEDETOMIDINE 19
Methylene Blue 15

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Hydrocortisone 1% 31
I.V. Meropenem 27
Blood Sampling 24
Vancomycin 1.1% 22
Daptomycin 6mg/kg/day 21

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Systemic Inflammatory Response Syndrome trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Disease complications experienced during 90 day follow up that required rehospitalization 1,241 1
Septic shock 519 44
Severe acute kidney injury 362 1
Cardiac arrest 344 33
Respiratory failure 319 48

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Systemic Inflammatory Response Syndrome? (559)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Pro-inflammatory cytokines in response to systemic inflammatory response syndrome post extra-corporeal membrane oxygenator decannulation. The International journal of artificial organs 2026 Yes
Protective effect of ulinastatin against negative inflammatory response and organ dysfunction in acute aortic dissection surgery: The PANDA trial. Cell reports. Medicine 2025 Yes
CMR Findings in the Long-Term Outcomes After Multisystem Inflammatory Syndrome in Children (MUSIC) Study. Circulation. Cardiovascular imaging 2025 Yes
Effect of thymosin α1 on Immune response and organ function in acute aortic dissection surgery: PANDA II trial protocol. Future cardiology 2025 Yes
Systemic inflammatory response to cemented and uncemented total hip arthroplasty with PMMA bone cement. Scientific reports 2025 Yes

Showing 5 of 559 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages